Determinants of VLDL composition and apo B-containing particles in familial combined hyperlipidemia

Clin Chim Acta. 2015 Jan 1:438:160-5. doi: 10.1016/j.cca.2014.08.018. Epub 2014 Aug 27.

Abstract

Background: In familial combined hyperlipidemia (FCHL) the severity of the dyslipidemia is determined by an overproduction of VLDL (very low density lipoprotein) particles and by its abnormal lipid composition. However, few are known regarding the metabolic factors that determine these abnormalities. We investigated the impact of metabolic factors on the number of atherogenic particles (apolipoprotein B level (apoB)) and the triglyceride content of very low-density lipoproteins (VLDLs-TG).

Methods: A cross-sectional study done in FCHL subjects and gender and age-matched healthy subjects. A clinical assessment, lipid profile and plasma concentrations of insulin, apolipoprotein CIII (apo CIII), apolipoprotein AII (apo AII), high sensitive C-reactive protein (HS-CRP), adiponectin and leptin were documented in 147 FCHL patients and 147 age-matched healthy subjects. Multivariate regression models were performed to investigate the independent determinants of VLDL-TG and apo B levels adjusting for confounding factors.

Results: The variables that determined the VLDL-triglyceride content as a surrogate of VLDL composition were apo CIII (β=0.365, p<0.001), insulin (β=0.281, p<0.001), Apo AII (β=0.145, p<0.035), and adiponectin levels (β=-0.255, p<0.001). This model explained 34% of VLDL composition (VLDL-TG) variability. However, none of these variables were independent contributors of apo B-containing particles.

Conclusions: In patients with FCHL apo CIII, apo AII and adiponectin are major novel factors determining the VLDL particle composition. However, such factors do not explain apo B-containing particles.

Keywords: Apolipoprotein CIII; Familial combined hyperlipidemia; VLDL particle number; VLDL triglyceride content.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Apolipoprotein C-III / blood
  • Apolipoproteins B / blood*
  • Biomarkers / blood*
  • Case-Control Studies
  • Cohort Studies
  • Cross-Sectional Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperlipidemia, Familial Combined / blood
  • Hyperlipidemia, Familial Combined / diagnosis*
  • Lipoproteins, VLDL / blood*
  • Male
  • Middle Aged
  • Prognosis
  • Triglycerides / blood*

Substances

  • Apolipoprotein C-III
  • Apolipoproteins B
  • Biomarkers
  • Lipoproteins, VLDL
  • Triglycerides
  • very low density lipoprotein triglyceride